Prostate Specific Antigen Doubling Time Calculation: Not as Easy as 1, 2, 4

Journal of Urology

Volumn 176, Issue 5, 2006, Pages 1927-1937

  Daskivich, Timothy J ^a   Regan, Meredith M ^a   Oh, William K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

decision support techniques; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

DATA BASE; HUMAN; MEDICAL LITERATURE; METHODOLOGY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW;

BLOOD CHEMICAL ANALYSIS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33750318797     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.07.002     Document Type: Review

References (31)

1. Hanks G.E., Hanlon A.L., Lee W.R., Slivjak A., and Schultheiss T.E. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34 (1996) 549
2. Egawa S., Arai Y., Tobisu K., Kuwao S., Kamoto T., Kakehi Y., et al. Use of pretreatment prostate specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3 (2000) S11
3. Goluboff E.T., Heitjan D.F., DeVries G.M., Katz A.E., Benson M.C., and Olsson C.A. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol 158 (1997) 1876
4. D'Amico A.V., and Hanks G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72 (1993) 2638
5. Sartor C.I., Strawderman M.H., Lin X.H., Kish K.E., McLaughlin P.W., and Sandler H.M. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 38 (1997) 941
6. Sandler H.M., Dunn R.L., McLaughlin P.W., Hayman J.A., Sullivan M.A., and Taylor J.M. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48 (2000) 629
7. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., and Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20 (2002) 4567
8. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Surrogate marker for prostate cancer-specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376
9. Trapasso J.G., deKernion J.B., Smith R.B., and Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152 (1994) 1821
10. Patel A., Dorey F., Franklin J., and deKernion J.B. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158 (1997) 1441
11. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
12. Roberts S.G., Blute M.L., Bergstralh E.J., Slezak J.M., and Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76 (2001) 576
13. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
14. Ward J.F., Zincke H., Bergstralh E.J., Slezak J.M., and Blute M.L. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172 (2004) 2244
15. Shulman M.J., and Benaim E.A. The natural history of androgen independent prostate cancer. J Urol 172 (2004) 141
16. Shulman M.J., Karam J.A., and Benaim E.A. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 63 (2004) 732
17. Loberg R.D., Fielhauer J.R., Pienta B.A., Dresden S., Christmas P., Kalikin L.M., et al. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology 62 (2003) 128
18. Schroder F.H., Kranse R., Barbet N., Hop W.C., Kandra A., and Lassus M. Prostate-specific antigen: a surrogate endpoint for screening new agents against prostate cancer?. Prostate 42 (2000) 107
19. Scher H.I., Eisenberger M., D'Amico A.V., Halabi S., Small E.J., Morris M., et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22 (2004) 537
20. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125
21. D'Amico A.V., Renshaw A.A., Sussman B., and Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440
22. Choo R., Klotz L., Deboer G., Danjoux C., and Morton G.C. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int 94 (2004) 295
23. Carter H.B., Morrell C.H., Pearson J.D., Brant L.J., Plato C.C., Metter E.J., et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 52 (1992) 3323
24. Kelloff G.J., Coffey D.S., Chabner B.A., Dicker A.P., Guyton K.Z., Nisen P.D., et al. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 10 (2004) 3927
25. American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncol (Williston Park) 14 (2000) 267
26. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035
27. Bubley G.J., Carducci M., Dahut W., Dawson N., Daliani D., Eisenberger M., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461
28. Link R.E., Shariat S.F., Nguyen C.V., Farr A., Weinberg A.D., Morton R.A., et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2,304 patients undergoing prostate cancer screening. J Urol 171 (2004) 2234
29. Ornstein D.K., Smith D.S., Rao G.S., Basler J.W., Ratliff T.L., and Catalona W.J. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 157 (1997) 2179
30. Prestigiacomo A.F., and Stamey T.A. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J Urol 155 (1996) 1977
31. Komatsu K., Wehner N., Prestigiacomo A.F., Chen Z., and Stamey T.A. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology 47 (1996) 343